Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.
Saved in:
| Title: | Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. |
|---|---|
| Authors: | Dizman N; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.; Yale University School of Medicine, New Haven, CT, USA., Meza L; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Bergerot P; Cettro Oncologia, Brasilia, Brazil., Alcantara M; Department of Immunology, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Dorff T; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Lyou Y; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Frankel P; Division of Biostatistics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Cui Y; Division of Biostatistics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Mira V; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Llamas M; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Hsu J; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Zengin Z; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Salgia N; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Salgia S; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Malhotra J; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Chawla N; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Chehrazi-Raffle A; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Muddasani R; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Gillece J; The Translational Genomics Research Institute (TGen), Phoenix, AZ, USA., Reining L; The Translational Genomics Research Institute (TGen), Phoenix, AZ, USA., Trent J; The Translational Genomics Research Institute (TGen), Phoenix, AZ, USA., Takahashi M; Miyarisan Pharmaceuticals, Co., Ltd., Tokyo, Japan., Oka K; Miyarisan Pharmaceuticals, Co., Ltd., Tokyo, Japan., Higashi S; Miyarisan Pharmaceuticals, Co., Ltd., Tokyo, Japan., Kortylewski M; Department of Immunology, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Highlander SK; The Translational Genomics Research Institute (TGen), Phoenix, AZ, USA. sarah@skhighlander.us., Pal SK; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. spal@coh.org. |
| Source: | Nature medicine [Nat Med] 2022 Apr; Vol. 28 (4), pp. 704-712. Date of Electronic Publication: 2022 Feb 28. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
